

1 **Rapid comparative evaluation of SARS-CoV-2 rapid point-of-care antigen tests**

2

3 Anna Denzler^{1, †}, Max L. Jacobs^{1, †}, Victoria Witte¹, Paul Schnitzler², Claudia M.
4 Denkinger^{3,*}, Michael Knop^{1,4,5,*}

5

6 **Affiliations:**

7 ¹ Center for Molecular Biology of Heidelberg University (ZMBH), Heidelberg,
8 Germany.

9 ² Department of Infectious Diseases, Virology, Heidelberg University Hospital,
10 Heidelberg, Germany.

11 ³ Department of Infectious Diseases, Division of Tropical Medicine, Heidelberg
12 University Hospital, Heidelberg, Germany.

13 ⁴ German Cancer Research Center (DKFZ), Heidelberg, Germany.

14 ⁵ DKFZ-ZMBH Alliance, Heidelberg, Germany.

15 * Corresponding authors.

16 † These authors contributed equally to this work.

17

18

19 **Keywords:** Comparison of Antigen-detecting rapid diagnostic test; COVID-19;
20 SARS-CoV-2; Testing sensitivity, non-functional AgPOC tests.

21

22

23

24 **Corresponding authors:**

25 Michael Knop

26 Center for Molecular and Cellular Biology Heidelberg, Heidelberg University,
27 Heidelberg, Germany

28 m.knop@zmbh.uni-heidelberg.de

29 +49 6221 54 4213

30 Claudia M. Denkinger

31 Division of Tropical Medicine, Center for Infectious Diseases, Heidelberg University
32 Hospital, Heidelberg, Germany

33 Claudia.Denkinger@uni-heidelberg.de

34 +49 6221 56 36637

35

Note: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

36 **Abstract**

37 **Background:** Currently, more than 500 different AgPOCTs for SARS-CoV-2
38 diagnostics are on sale, for many of which no data about sensitivity other than self-
39 acclaimed values by the manufacturers are available. In many cases these do not
40 reflect real-life diagnostic sensitivities. Therefore, manufacturer-independent quality
41 checks of available AgPOCTs are needed, given the potential implications of false-
42 negative results.

43 **Objective:** The objective of this study was to develop a scalable approach for direct
44 comparison of the analytical sensitivities of commercially available SARS-CoV-2
45 antigen point-of-care tests (AgPOCTs) in order to rapidly identify poor performing
46 products.

47 **Methods:** We present a methodology for quick assessment of the sensitivity of
48 SARS-CoV-2 lateral flow test stripes suitable for quality evaluation of many different
49 products. We established reference samples with high, medium and low SARS-CoV-
50 2 viral loads along with a SARS-CoV-2 negative control sample. Test samples were
51 used to semi-quantitatively assess the analytical sensitivities of 32 different
52 commercial AgPOCTs in a head-to-head comparison.

53 **Results:** Among 32 SARS-CoV-2 AgPOCTs tested, we observe sensitivity
54 differences across a broad range of viral loads ($\sim 7.0 \times 10^8$ to $\sim 1.7 \times 10^5$ SARS-CoV-2
55 genome copies per ml). 23 AgPOCTs detected the Ct25 test sample ($\sim 1.4 \times 10^6$
56 copies/ ml), while only five tests detected the Ct28 test sample ($\sim 1.7 \times 10^5$ copies/
57 ml). In the low range of analytical sensitivity we found three saliva spit tests only
58 delivering positive results for the Ct21 sample ($\sim 2.2 \times 10^7$ copies/ ml). Comparison
59 with published data support our AgPOCT ranking. Importantly, we identified an
60 AgPOCT offered in many local drugstores and supermarkets, which did not reliably
61 recognize the sample with highest viral load (Ct16 test sample with $\sim 7.0 \times 10^8$ copies/
62 ml) leading to serious doubts in its usefulness in SARS-CoV-2 diagnostics.

63 **Conclusion:** The rapid sensitivity assessment procedure presented here provides
64 useful estimations on the analytical sensitivities of 32 AgPOCTs and identified a
65 widely-spread AgPOCT with concerning low sensitivity.

66

67

68 **Funding:** The study was supported by the Ministry of Science, Research and Arts of
69 the State of Baden-Wuerttemberg, Germany as well as internal funds from the
70 Heidelberg University Hospital. The corresponding authors had access to all data at
71 all time.

72

73 **Introduction**

74 In the SARS-CoV-2 pandemic, lateral-flow antigen tests were developed as a rapid
75 alternative to SARS-CoV-2 reverse transcriptase quantitative polymerase chain
76 reaction (RT-qPCR) based diagnostics. Because of their ease of use, lateral-flow
77 antigen tests are applicable for point-of-care and self testing and can therefore be
78 incorporated in the daily life to support viral containment (WHO, Interim guidance,
79 2020). These tests, in the following referred to as antigen point-of-care tests
80 (AgPOCTs), are meanwhile widely used for SARS-CoV-2 diagnostic and screening
81 purposes. Currently, several hundred different SARS-CoV-2 AgPOCTs brands are
82 commercially available to meet the demand (545 products for professional use are
83 listed by the Federal Institute for Drugs and Medical Devices (Bundesinstitut für
84 Arzneimittel und Medizinprodukte (BfArM)); as of July 27, 2021). However,
85 sensitivity and specificity of the tests are not systematically assessed.

86 If a test is used by a professional operator, it falls under the 'low-risk' category of the
87 European Union directive on In Vitro Diagnostics (IVD), which currently governs
88 marketing authorization for IVDs in Europe. Under this directive, manufacturers can
89 still self-certify COVID-19 tests and waive independent verification of the tests before
90 they are marketed. The validation of the tests, which are offered on the Internet and
91 in pharmacies, is therefore not assured in the view of the Paul Ehrlich Institute (PEI),
92 Federal Institute for Vaccines and Biomedical Products, Germany
93 ([https://www.pei.de/DE/newsroom/hp-meldungen/2020/200323-covid-19-nat-](https://www.pei.de/DE/newsroom/hp-meldungen/2020/200323-covid-19-nat-tests.html;jsessionid=F786872EBB85959AE8DA2B8FCB3ABE00.intranet222?nn=169730)
94 [tests.html;jsessionid=F786872EBB85959AE8DA2B8FCB3ABE00.intranet222?nn=16](https://www.pei.de/DE/newsroom/hp-meldungen/2020/200323-covid-19-nat-tests.html;jsessionid=F786872EBB85959AE8DA2B8FCB3ABE00.intranet222?nn=169730)
95 [9730](https://www.pei.de/DE/newsroom/hp-meldungen/2020/200323-covid-19-nat-tests.html;jsessionid=F786872EBB85959AE8DA2B8FCB3ABE00.intranet222?nn=169730)). There is also evidence of counterfeiting here. A new legislation governing
96 independent validation by specialized and certified reference laboratories is planned,
97 but will only become effective in March 2022 at the earliest.

98 If a test is distributed for layperson use, it falls under a ‘higher-risk’ category and
99 requires independent validation. This validation of sensitivity is currently performed
100 by the PEI together with reference laboratories and a list with AgPOCTs passing their
101 criteria is provided (PEI, 2021). AgPOCTs failing the comparative evaluation by PEI
102 will be removed from the list provided by BfArM. This list, however, comprises only
103 products, which were also registered for listing by manufacturers or distributors
104 ([https://www.bfarm.de/DE/Medizinprodukte/Aufgaben/Spezialthemen/Antigentests/_n](https://www.bfarm.de/DE/Medizinprodukte/Aufgaben/Spezialthemen/Antigentests/_node.html)
105 [ode.html](https://www.bfarm.de/DE/Medizinprodukte/Aufgaben/Spezialthemen/Antigentests/_node.html)), rendering the absence of an AgPOCT from this list difficult to interpret.

106 Many in-depth AgPOCT characterization studies show that AgPOCT sensitivities can
107 vary substantially. One study reporting on the validation of 122 AgPOCs has recently
108 been published (Scheiblaue *et al.*, 2021). They found that 26 AgPOCTs do not fulfill
109 the required minimum sensitivity, clearly illustrating that quite a number of circulating
110 AgPOCT are insufficiently sensitive. In addition to this, significant brand-to-brand and
111 lot-to-lot variations were observed (Dinnes *et al.*, 2021). These circumstances urge
112 the need for an easy-to-use method to quickly assess AgPOCTs at market entry and
113 periodically thereafter for post-implementation quality control.

114 In this study, we sought to establish a procedure to rapidly evaluate a large number
115 of products for their sensitivity, using only a few samples and tests per product. For
116 this we developed a strategy involving pooled samples and four different dilution
117 steps from high to low viral loads, and generated several hundred aliquots thereof.
118 Using this approach we then investigated 32 AgPOCTs, mainly tests currently in use
119 in the local area (Heidelberg, Germany). We compared the results with data from the
120 literature, which enabled us to draw conclusions on the validity of our approach and
121 the performance of the products investigated.

122 **Methods**

123 **Study design**

124 We tested the analytical sensitivity of a large number of commercially available
125 AgPOCTs by applying pooled samples from nasopharyngeal swabs with defined
126 SARS-CoV2 viral loads including Ct16, Ct21, Ct25 and Ct28 ($\sim 7.0 \cdot 10^8$ to $\sim 1.7 \cdot 10^5$
127 genome copies per ml) as well as a pooled sample obtained from SARS-CoV-2
128 negative tested persons. Pools were generated using pseudo-anonymized remnant
129 swab sample material that had been collected for clinical diagnosis of SARS-CoV-2
130 infection by RT-qPCR carried out by the Center for Infectious Diseases, Virology,
131 Heidelberg University Hospital, Germany. Pharyngeal swab specimens were
132 collected through the nose (nasopharyngeal) and contained in viral transport medium
133 (VTM). Per test, 50 μ l of the samples were mixed with the provided lysis buffer of
134 each AgPOCT and the tests were performed according to the manufacturer's
135 instructions. After the recommended incubation time, images of the test chambers
136 were acquired using a Panasonic Lumix DMC-G70 camera equipped with a
137 Panasonic H-FS12060 objective. AgPOCTs were tested at least in duplicates with
138 the corresponding test samples. Test results were quantified by measuring the
139 background corrected signal intensities of the test (T) band versus control (C) band in
140 ImageJ (v1.53c) using the "Gels" analysis function usually used for quantification of
141 Western Blot bands. For qualitative evaluation of the visibility of the test bands
142 (positive versus negative score), RGB pictures of AgPOCT results from randomly
143 chosen replicates were evaluated independently by three individuals in a blinded
144 manner. Furthermore, all additional replicates of all AgPOCTs and test samples were
145 scored independently by another person.

146 **Preparation of test samples from nasopharyngeal swabs**

147 Anonymized, remnant nasopharyngeal swab samples positively and negatively
148 tested for SARS-CoV-2 were obtained between May and July 2021 from the the
149 Center for Infectious Diseases, Virology, Heidelberg University Hospital, Germany.
150 Samples were stored in VTM. The Ct16, Ct21 and negative test samples were
151 prepared by pooling of 12-15 nasopharyngeal swab samples. Cell debris and other
152 solids were removed by centrifugation at 400g for 10min and subsequent transfer of
153 the supernatant into a new tube. Viral RNA was isolated from pools by manual lysis
154 and automated RNA extraction using the QIAamp Viral RNA Mini kit (Qiagen) on a
155 QIAcube Connect device (Qiagen). The cycle threshold (Ct) values of sample pools
156 were determined by RT-qPCR analysis using the LightMix® Modular Sarbecovirus
157 SARS-CoV-2 (TIB Molbiol) with the LightCycler® Multiplex RNA Virus Master
158 (Roche) and LightCycler480 II (Roche). Subsequently, pools were supplemented with
159 2 % TritonX-100 and c0mplete Ultra protease inhibitor (Roche) and if needed
160 adjusted with dilution buffer [2 mg/ ml BSA, 0.9 % NaCl, protease inhibitor]. Ct25 and
161 Ct28 test samples were prepared by dilution of the Ct21 test sample in the dilution
162 buffer. Samples were aliquoted (120 µl), immediately frozen on dry ice and stored at -
163 80°C. For AgPOCT testing, samples were freshly thawed on ice before use. Test
164 samples were validated using the SARS-CoV-2 Antigen Test by LumiraDx.

165 **AgPOCTs evaluated in this study**

166 We included a total of 32 AgPOCTs available at local supermarkets, pharmacies and
167 drugstores as well as on several online trade platforms (Table 1). Specific AgPOCTs
168 will be referred to as the respective manufacturer's name (in bold in Table 1). The
169 inspected AgPOCTs include both, tests for professional *in vitro* diagnostics use (#1-
170 14) as well as tests temporarily licensed for self-testing in Germany (#15-32) by the
171 Federal Institute for Drugs and Medical Devices (Bundesinstitut für Arzneimittel und
172 Medizinprodukte (BfArM); Supplemental Figure S3). The majority of AgPOCTs
173 available were nasal swab tests with the exception of BTNX, Ritter, Joinstar, Realy
174 (#11-14) among the tests for professional use and Sanicom, Hygisun, fameditec
175 (#30-32) among the self tests, which are all saliva spit tests, as well as Watmind
176 (#29), which is a saliva swab test.

Table 1: AgPOCTs investigated in this study. For each AgPOCT supplier, name, reference and LOT number are indicated. If tests obtained a temporary license for self-testing in Germany the corresponding BfArM GZ number is given as well. In addition, sample type and professional (pro) versus layman (lay) use is indicated. In the last column the type of distributor where AgPOCTs were purchased is noted.

#	Supplier	AgPOCT name	Specifications	Sample type	Use	Distributor
1	Abbott Rapid Diagnostics Jena GmbH	Panbio COVID-19 Ag Rapid test device (nasal)	REF: 41FK11 LOT: 41ADG244A	Nasal swab	pro	Online trade
2	Healgen Scientific Limited Liability Company	Coronavirus Ag Rapid Test Cassette (Swab)	REF: GCCOV-502a LOT: 2012650	Nasopharyngeal swab	pro	Online trade
3	RapiGEN , INC.	Biocredit COVID-19 Ag – One step Rapid Test	REF: G61RHA20 LOT: H073097SD	Nasopharyngeal swab	pro	Online trade
4	Beijing Beier Bioengineering Co., Ltd	COVID-19 Antigen Rapid Test Kit	REF: not specified LOT: 20210201	Nasopharyngeal swab	pro	Online trade
5	möLab GmbH	mö-screen Testkit Corona Antigen	REF: 0230005B1 LOS: 2104072	Nasal/ Nasopharyngeal swab	pro	Online trade
6	Biomerica , Inc.	COVID-19 Antigen Rapid Test	REF: 1509A-25I LOT: COV6686	Nasopharyngeal swab	pro	Online trade
7	Joysbio (Tianjin) Biotechnology Co., Ltd	JOYSBIO SARS-CoV-2 Antigen Rapid Test Kit (Colloidal Gold)	REF: G10313 LOT: 2021011607	Nasopharyngeal swab	pro	Online trade

8	Safecare Biotech (Hangzhou) Co., Ltd	COVID-19 Antigen Rapid Test Kit (Swab)	REF: COV Ag-6012 LOT: COV21040606	Nasopharyngeal swab	pro	Online trade
9	Hangzhou Testsea Biotechnology Co., Ltd	Testsealabs COVID-19 Antigen Test Cassette	REF: 2020013 vB/10 LOT: TL1C05	Nasal swab	pro	Online trade
10	ACON Biotech (Hangzhou) Co., Ltd	Flowflex SARS-Cov-2-Antigen- Schnelltest (Selbsttest)	REF: L031-11855 LOT: COV1030052	Nasal swab	pro	Online trade
11	BTNX Inc.	Rapid Response COVID-19 Antigen Rapid Test Cassette	REF: COV-2C25B LOT: COVG21030089	Saliva (spit)	pro	Online trade
12	Joysbio (Tianjin) Biotechnology Co., Ltd/ Ritter	Easy Check Spit test SARS- CoV-2 Antigen Rapid Test Kit (Colloidal Gold)	REF: COV-AG-20/ G10313 LOT: 20210202	Saliva (spit)	pro	Online trade
13	Joinstar Biomedical Technology Co., Ltd.	COVID-19 Antigen Rapid Test (Latex)	REF: RPBH12360 LOT: COV2103002L	Saliva/ sputum (spit), stool	pro	Online trade
14	Hangzhou Realy Tech Co., Ltd	Novel Coronavirus (SARS- CoV-2) Antigen Rapid Test Device (Saliva)	REF: K590516D LOT: 202101022	Saliva (spit)	pro	Online trade
15	nal von minden GmbH	NADAL COVID-19 Ag Test	REF: 243103N-20H LOT: 175363 BfArM GZ: 5640-S-045/21	Nasal swab	lay	Online trade

16	SD Biosensor	SARS-CoV-2 Rapid Antigen Test	REF: 9901-NCOV-01G LOT: QCO390092I BfArM GZ: 5640-S-025/21	Nasal swab	lay	Online trade
17	Beijing Hotgen Biotech Co., Ltd	Coronavirus (2019-nCoV)-Antigentest	REF: 4260220532859 LOT: W2021032500/ W2021032602/ 1500 BfArM GZ: 5640-S-057/21	Nasal swab	lay	Supermarket Pharmacy
18	Guangzhou Wondfo Biotech Co., Ltd.	2019-nCoV Antigen Test (Lateral Flow Method)	REF: W634P0021 LOT: W634104116 BfArM GZ: 5640-S-179/21	Nasal swab	lay	Supermarket
19	Teda Laukoetter Technology GmbH	COVID-19 Antigen Schnelltest (kolloidales Gold) ANBIO Corona Antigen Nasentupfer	REF: A6061214 LOT: 2021046133/ 461310/036138 BfArM GZ: 5640-S-079/21	Nasal swab	lay	Drug store
20	Beijing Lepu Medical Technology Co., Ltd	NASOCHECKcomofort SARS-CoV-2 Antigen-Schnelltest	REF: CG2701N LOT: 21CG2720X/ 18X BfArM GZ: 5640-S-104/21	Nasal swab	lay	Drug store
21	Hangzhou Clongene Biotech Co., Ltd	COVID-19 Antigen Rapid Test	REF 6950921302636 LOT: 2021030161 BfArM GZ: 5640-S-168/21	Nasal swab	lay	Online trade
22	Hangzhou Laihe Biotech Co., Ltd	LYHER Novel Coronavirus (COVID-19) Antigen Test Kit (Colloidal Gold) NASAL	REF: 303036 LOT: 2103049/47/ 89-01 BfArM GZ: 5640-S-009/21	Nasal swab	lay	Pharmacy

23	MP Biomedicals Germany GmbH	Rapid SARS-Cov-2 Antigen Test Card	REF: 07AG6001BS LOT: 21033003 BrArM GZ: 5640-S-076/21	Nasal swab	lay	Supermarket
24	Xiamen Boson Biotech Co., Ltd	Rapid SARS-CoV-2 Antigen Test Card	REF: 1N40C5-4 LOT: 21040609 BfArM GZ: 5640-S-007/21	Nasal swab	lay	Supermarket
25	NanoRepro AG	VIROMED for the detection of SARS-Cov-2 from anterior nasal swab	REF: B60500 LOT: 20210401B BrArM GZ: 5640-S-096/21	Nasal swab	lay	Drug store
26	Anhui Deepblue Medical Technology Co., Ltd	COVID-19 (SARS-CoV-2) Antigentestkit (kolloidales Gold)	REF: SL030101N-5 LOT: ST210405 BfArM GZ: 5640-S-086/21	Nasal swab	lay	Online trade
27	OFM GmbH	Deni COVID-19 Antigen Test – Selbsttest für Zuhause	REF: OFM-LSYBT-NS-1 LOT: P202103003 BfArM GZ: 5640-S-140/21	Nasal swab	lay	Drug store
28	Medice Arzneimittel Pütter GmbH & Co. KG	Medicovid-AG SARS-CoV-2 Antigen Selbsttest 5 NASE	REF: 1N40C5-4 LOT: 21041002 BfArM GZ: 5640-S-128/21	Nasal swab	lay	Online trade
29	Shenzhen Watmind Medical Co., Ltd	SARS-CoV-2 Antigen Schnelltest zur Eigenanwendung (kolloidales Gold)	REF: LFA0401-5N LOT: 21040904/ 21040704 BfArM GZ: 5640-032/21	Saliva (swab)	lay	Supermarket

30	MR Sanicom GmbH	COVID-19 Antigen Schnelltest zur Eigenanwendung (Speichel-/ Spucktest)	Barcode no: 4260729310002 LOT: CAG2104021G BfArM GZ: 5640-S-147/21	Saliva (spit)	lay	Drug store
31	Hygisun Anbio (Xiamen) Biotechnology Co., Ltd.	COVID-19 Antigen Schnelltest (kolloidales Gold)	REF: A6061213 LOT: 2021046132/ 2021036136/ 2021036137 BfArM GZ: 5640-S-058/21	Saliva (spit)	lay	Drug store
32	fameditec	CORA Check-19 Comfort	REF: K590516D/ LOT: 2021022019 BfArM GZ: 5640-S-154/21	Saliva (collected with sponge)	lay	Online trade

177 **Results**

178 **Generation of test samples for standardized AgPOCT evaluation**

179 In the present study, we sought to establish a standardized procedure to rapidly
180 assess the sensitivities of a large number of SARS-COV-2 AgPOCTs. To this end,
181 we generated a collection of test samples from pooled nasopharyngeal swabs from
182 SARS-CoV-2 positive tested and negative tested individuals. Ct values of the SARS-
183 CoV-2 positive pools were determined by RT-qPCR and test samples were prepared
184 accordingly. The test sample collection comprised four SARS-CoV-2 positive pools
185 with defined viral loads (Ct16, Ct21, Ct25, Ct28) and one SARS-CoV-2 negative pool.
186 Per test sample, >200 aliquots with 120 µl sample volume each were prepared,
187 allowing a quick and standardized evaluation of the analytical sensitivities of a large
188 number of different AgPOCTs.

189 We estimated that our test sample collection covers a range from $\sim 7.0 \times 10^8$ (Ct=16) to
190 $\sim 1.7 \times 10^5$ (Ct=28) SARS-CoV-2 genome copies per ml (Supplemental Table S4). We
191 qualitatively validated our test sample collection using the LumiraDx SARS-CoV-2 Ag
192 Test device, which was shown to have a high analytical sensitivity (Krüger *et al.*,
193 2021). We used 50 µl of test sample for the LumiraDx analysis as well as for all
194 AgPOCTs evaluated in this study, as described before (Corman *et al.*, 2021;
195 Puyskens *et al.*, 2021). All four SARS-CoV-2 positive test samples tested positive for
196 SARS-CoV-2, while the negative test sample was recognized as negative in the
197 LumiraDx analysis.

198 **Quantitative and qualitative assessment of AgPOCT analytical sensitivity**

199 We tested a total of 32 AgPOCTs (Table 1). 12 AgPOCTd were purchased from local
200 resellers (pharmacies, drugstores, supermarkets). Another 20 tests were purchased
201 online. We performed the tests over 10 days, with the help of four students, during
202 the course of four weeks. Freshly thawed aliquots of the Ct21, Ct25, and Ct28 test
203 samples as well as the negative sample were used. We conducted two to four
204 replicates per product, and acquired images of each of the tests at the time points
205 specified by the manufacturers. The Ct16 test sample was only used for AgPOCTs
206 that had low performance with the Ct21 test sample. For quantitative evaluation,
207 signal intensities of the test and the control bands were measured and the ratio of
208 these values (T/C ratio) was determined (Figure 1A). In addition, we scored a binary
209 (positive or negative) test result using visual inspection of the images by four different
210 persons (Figure 1B).

211 For 31 of 32 investigated AgPOCTs, an average $T/C_{Ct25} > 0$ was determined for all
212 virus-containing samples and not for the negative control sample (Figure 1A). This
213 indicates that the digital quantification detects test band signals for 31 AgPOCTs
214 using the Ct25 test sample, albeit sometimes with extremely weak signal intensities.
215 Only for Jointstar, one replicate of the negative test sample resulted in a false-
216 positive test band indicated by a $T/C_{Neg.} > 0$. In contrast to the more sensitive digital
217 quantification, visual inspection did only score a positive result for 28 of 31 AgPOCTs
218 with a $T/C_{Ct25} > 0$. This also holds true for the visual assessment of the results of
219 technical replicates, e.g. for Jointstar, the negative sample with a $T/C_{Neg.} > 0$ scored
220 negative in the visual inspection. We could not establish a specific T/C value
221 threshold to explain the results of the visual assessment, indicating that these ratios
222 are AgPOCT-specific. This can be explained by different dyes and dye-systems, and

223 by the fact that the visual assessment was conducted using color vision, while for T/C
224 quantification grayscale images were used. We also observed a large coefficient of
225 variation for some of the tests, in particular for samples with very small T/C ratios,
226 emphasizing weak signals close to the detection limit of the digital quantification
227 (Supplemental Figure S1).

228 We grouped the tested AgPOCT into categories with low (Group III), medium (Group
229 II) and high (Group I) sensitivity based on the reliability to detect a given SARS-CoV-
230 2 positive sample. A sample was considered reliably detected by a given AgPOCT
231 when all or the majority of replicates (at least two out of three or three out of four
232 replicates) of a given sample were scored positive. If none or the minority of
233 replicates of a given sample was detected by the corresponding AgPOCT, reliability
234 requirements were not met.

235 One exception was Lepu Medical, which did not fulfill the requirements for any of
236 these groups. For Group III with lowest sensitivity the minimum criterion was to
237 reliably detect the Ct21 sample and Lepu medical did not even reliably score positive
238 with the Ct16 sample ($\sim 7.0 \cdot 10^8$ copies/ ml). To investigate this product further and
239 exclude a possible interference of the components in the dilution buffer with AgPOCT
240 performance we used individual unprocessed nasal/ nasopharyngeal swab samples
241 in comparison to the Ct16 test sample (pool) on this AgPOCT. Ct values of
242 unprocessed samples ranged from Ct13,3 to Ct18,4. Comparison of the
243 corresponding results obtained for the Ct16 test sample to results obtained for
244 unprocessed samples confirmed that components of the dilution buffer do not impact
245 on AgPOCT performance compared to unprocessed samples in VTM (Supplemental
246 Figure S2). As unprocessed samples with higher viral loads (Ct \sim 13) induced more
247 visible test bands with Lepu medical (Supplemental Figure S2A), this product does

248 not seem completely non-functional, but rather largely insensitive.
249 AgPOCTs in Group III only reliably detected the Ct21 sample ($\sim 2.2 \times 10^7$ copies/ml)
250 and include Hygisun, Joinstar and Ritter. Of note is that all of them are saliva based
251 spit tests (Table 1), which are provided with a considerably larger amount of lysis
252 buffer (500-1000 μ l lysis buffer; Figure 1C) than most other AgPOCTs resulting in an
253 increased dilution of the sample compared to tests for nasal samples, which are
254 provided on average with 320 μ l lysis buffer (Figure 1C). Therefore, their low
255 performance in this AgPOCT evaluation study needs to be interpreted with caution.
256 The large majority of the investigated AgPOCTs (23 out of 32) delivered visible
257 positive results with the Ct25 sample ($\sim 1.4 \times 10^6$ copies/ml, Group II). Among these
258 23 AgPOCTs, positive scoring was fully reproducible in all replicates for 17
259 AgPOCTs. AgPOCTs intended for professional use (sorted ascending according to
260 T/C_{Ct25} : Safecare, Realy, Healgen, ACON, Beier, Testsea, BTNX and Biomerica)
261 largely cluster in the upper half of the T/C_{Ct25} ranking, while tests licensed for self-
262 testing largely cluster in the lower half (sorted ascending according to T/C_{Ct25} :
263 Sanicom, fameditec, OFM, Deepblue, NanoRepro, nal von minden, Teda, Laihe and
264 Boson). Interestingly, among both tests for professional and for layman use, saliva
265 spit tests (Realy, Sanicom, fameditec) appear largely inferior compared to nasal
266 swab tests with the exception of BTNX, which is the sixth highest ranked AgPOCT
267 among all investigated tests. Six AgPOCTs in Group II (sorted ascending according
268 to T/C_{Ct25} : Joysbio, RapiGEN, Hotgen, SD Biosensor, Abbott and Wondfo) failed in
269 one out of three to four replicates to detect the Ct25 sample, which is represented by
270 a large coefficient of variation (Supplemental Figure S1).
271 Using the Ct28 test sample ($\sim 1.7 \times 10^5$ copies/ml), 14 out of 32 AgPOCTs yielded a
272 $T/C_{Ct28} > 0$, however, only five reliably scored positive in the visual investigation
273 (Group I). These include (sorted in ascending order according to T/C_{Ct25}) möLab,

274 Medice, MP, Clongene and Watmind, three of which are temporarily licensed for self-
275 testing (Table 1, Supplemental Figure S3). All, except möLäb delivered a positive
276 visual result in all three replicates.

277 Taken together, the data presented here demonstrate that the different SARS-CoV-2
278 AgPOCTs available deviate largely in the analytical sensitivity of the lateral flow test
279 stripes and provided buffer systems, corresponding more than two orders of
280 magnitude of viral genome copies per ml ($7.0 \cdot 10^8$ to $1.7 \cdot 10^5$).

281

282 **Discussion**

283 We developed a straight-forward strategy to evaluate the technical sensitivity of
284 AgPOCTs for SARS-CoV-2. Using a set of four SARS-CoV-2 positive reference
285 samples spanning the relevant dynamic range of the typical sensitivity of AgPOCTs
286 ($\sim 1.7 \cdot 10^5$ to $\sim 2.2 \cdot 10^7$ SARS-CoV-2 genome copies per ml) we were able to group 32
287 commercially available products into AgPOCT groups with high, average and low
288 sensitivity (Group I-III). Most importantly, we identified one product that did not detect
289 any of the test samples and therefore is considered not suitable for SARS-CoV-2
290 diagnostics.

291 The majority of tests investigated in this study reliably detected the Ct25 test sample
292 as SARS-CoV-2 positive (Group II). Some of these AgPOCTs have been thoroughly
293 characterized, including Abbott, RapiGEN, Healgen, nal von minden and SD
294 Biosensor by Corman and colleagues (Corman *et al.*, 2021) among others (Strömer
295 *et al.*, 2021; Stokes *et al.*, 2021; Merino *et al.*, 2021; Schildgen *et al.*, 2021;
296 Seynaeve *et al.*, 2021; Nordgren *et al.*; Puyskens *et al.*, 2021; Scheiblaue *et al.*,
297 2021; Kohmer *et al.*, 2021; Wagenhäuser *et al.*, 2021; Berger *et al.*, 2021;

298 Jegerlehner *et al.*, 2021; Iglò *et al.*, 2021; Bekliz *et al.*, 2021; Cubas-Atienzar *et al.*,
299 2021, Haage *et al.*, 2021 and more). Corman and colleagues determined 95% limits
300 of detection for each AgPOCT using 138 SARS-CoV-2 positive clinical samples with
301 viral loads ranging from $1.9 \cdot 10^4$ to $1.8 \cdot 10^9$ genome copies per ml. Among the
302 AgPOCTs also tested in this study, Healgen was found to be most sensitive closely
303 followed by Abbott, SD Biosensor and nal von minden - all with a 95% limit of
304 detection between $2.3 - 9.3 \cdot 10^6$ SARS-COV-2 genomes per swab. In contrast, for
305 RapiGEN a 95% limit of detection more than three orders of magnitudes lower was
306 found. This discrepancy in performance between RapiGEN and the above mentioned
307 products is supported by other studies (Brümmer *et al.*, 2021). In our analysis, this
308 trend is also reflected even though we cannot resolve the limits of detection in such
309 great detail: For Healgen and nal von minden, detection of the Ct25 sample
310 ($\sim 1.4 \cdot 10^6$ copies/ ml) was robust with all replicates being positively scored. For
311 RapiGEN, Ct25 test sample detection was less reliable and based on the T/C_{Ct25} , this
312 product is ranked in the lowest quarter among all AgPOCTs investigated.

313 Among the 32 investigated AgPOCTs, we identified four reliably well performing
314 AgPOCTs, which detected the Ct28 sample ($\sim 1.7 \cdot 10^5$ copies/ ml) as SARS-CoV-2
315 positive in all replicates (Group I). These include in ascending order (based on
316 T/C_{Ct25}) Medice, MP, Clongene and Watmind. The latter represents the test winner in
317 our study and is also among the best three AgPOCTs out of 122 tested products with
318 a sensitivity of 82 % in samples with Ct values ranging from 17 to 35 corresponding
319 to viral loads of $>10^8$ to 10^3 SARS-CoV-2 genome copies per ml (Scheiblauer *et al.*,
320 2021).

321 Group III includes AgPOCTs with low performance as these only detected the Ct21
322 test sample as SARS-CoV-2 positive. For Joinstar, using Latex beads for

323 visualisation, evidence provided by Scheiblaue and colleagues (2021) suggests that
324 this test is non-functional with 0% sensitivity for all sample panels supporting the low
325 ranking of Joinstar in this study. In our analysis we detected very weak bands for the
326 Ct21 and Ct16 test samples, however, these were considerably weaker than for all
327 other tests suggesting the possibility that latex beads used for visualisation do fail to
328 produce a strong signal. Besides Joinstar, Ritter and Hygisun, both saliva spit tests
329 similar to Joinstar, also showed low sensitivity in our studies. While we could not find
330 independent evaluation studies for these products, both can be found on the BfArM
331 list (as of July 23, 2021; Supplemental Figure S3). Among the low ranked AgPOCTs,
332 the sensitivity of Lepu medical was exceptionally low as this AgPOCT failed to deliver
333 a visible positive test result in most replicates, even for the Ct16 sample. In addition
334 to its poor performance in SARS-CoV-2 diagnostics, out of 20 performed Lepu
335 medical tests three tests technically failed, indicated by the absence of the control
336 band. Importantly, this last test is a very popular product in the area where this study
337 was conducted, available at many drugstores and supermarket chains. Of note is
338 also that Lepu medical differs from other AgPOCTs in its design and sample
339 application. Technical failure did not occur in any of the other AgPOCTs, in which the
340 immunochromatography paper is embedded in the common plastic cassettes.

341 Taken together, comparison with published data for some of the investigated
342 products confirmed our results. Therefore, we provide evidence that a rapid
343 assessment of the sensitivity of SARS-CoV-2 AgPOCTs is feasible.

344 It is important to mention that the volume of the lysis buffer provided with each
345 AgPOCT varies between tests of different manufacturers resulting in a 2.6- to 20-fold
346 dilution of the test samples during the procedure (Figure 1C). In this study, test
347 results were not corrected for these different dilution factors, because the sample

348 dilution is an internal property of each test. Additionally, it is important to note that by
349 using the same sample volume for each AgPOCT potential differences in swab
350 properties, such as absorption volume, which affect the diagnostic sensitivity of
351 AgPOCTs, are neglected. However, we note that for tests based on nasal swabs the
352 used volume of 50 ul approximates the quantity absorbed by these swabs (Corman
353 *et al.*, 2021). Furthermore, there are AgPOCT-specific instructions for self-sampling,
354 which can also influence the diagnostic sensitivity of a test. In light of these
355 considerations we want to emphasize that this evaluation method only and
356 exclusively focuses on comparing the technical sensitivity of the lateral flow test
357 strips from different test manufacturers, in combination with the provided lysis
358 buffers.

359 Currently, there are more than 500 different products available for SARS-CoV-2
360 diagnostics, many of which lack independent assessment of their performance. In
361 most cases the clinical sensitivity values provided by the manufacturer (e.g. in Figure
362 1C) are far >90%, however, detailed information on the used specimen collection and
363 viral loads are usually not provided rendering these values largely inconclusive.
364 Considering that individual products use different antibodies in varying amounts with
365 different specificities and affinities sometimes recognizing different proteins in the
366 viral particle with differing abundances, and diverse staining methods, these
367 conspicuously similar values for clinical sensitivity given by the manufacturer are also
368 unlikely. Therefore, an independent, rapid and critical evaluation of AgPOCTs
369 available is required in order to determine the realistic performance of AgPOCT and
370 especially to identify poor performing products. Given the huge number of products
371 available for rapid SARS-CoV-2 diagnostics, in-depth studies evaluating the quality of
372 AgPOCTs in a time-intensive procedure will not be available any time soon for all
373 products available. Here we identify a non-functional product (Lepu medical) for

374 SARS-CoV-2 diagnostics, which was and still is (as of July 26, 2021) widely present
375 in the region of Heidelberg, Germany, emphasizing the urgent need for AgPOCT
376 products to undergo better and especially faster producer-independent quality
377 control. The procedure presented here involving a reduced test sample collection and
378 minimal labor represents a feasible strategy for prompt evaluation of available
379 AgPOCTs for their usability in SARS-CoV-2 diagnostics. We provide a useful
380 estimation of the limits of detection for the investigated AgPOCTs as the dimensions
381 and trends are comparable to results from much more laborious in-depth studies.
382 Therefore, we suggest this procedure as a rapid alternative to investigate Covid-19
383 AgPOCs in the absence of reliable data that validate the performance of a specific
384 product.

A	Means of T/C ratios					B	Pos. scores/ replicas					C	Additional information			
	Ct16	Ct21	Ct25	Ct28	Neg.		Ct16	Ct21	Ct25	Ct28	Neg.		n	Sensitivity	Lysis buffer [µl]	Dil. factor
Watmind	n.d.	1,81	0,51	0,08	0,00	n.d.	3/3	4/4	3/3	0/2	2-4	90,45	300	6		
Clongene	n.d.	1,38	0,48	0,10	0,00	n.d.	3/3	4/4	4/4	0/3	3-4	91,4	300	6		
MP	n.d.	1,08	0,28	0,04	0,00	n.d.	3/3	3/3	3/3	0/2	2-3	96,19	250	5		
Boson	n.d.	1,05	0,22	0,02	0,00	n.d.	3/3	5/5	1/2	0/2	2-5	96,19	200	4		
Biomerica	n.d.	0,78	0,22	0,06	0,00	n.d.	3/3	3/3	1/3	0/3	3	94,7	300	6		
BTNX	n.d.	1,04	0,21	0,01	0,00	n.d.	3/3	3/3	0/3	0/3	3	90,6	300	6		
Medice	n.d.	0,92	0,20	0,03	0,00	n.d.	2/2	2/2	2/2	0/2	2	96,19	250	5		
Testsea	n.d.	0,79	0,16	0,01	0,00	n.d.	3/3	3/3	0/3	0/3	3	97,6	300	6		
Beier	n.d.	1,75	0,15	0,00	0,00	n.d.	2/2	2/2	0/2	0/2	2	96,5	450	9		
Laihe	n.d.	1,03	0,15	0,01	0,00	n.d.	3/3	4/4	1/3	0/2	2-4	95	300	6		
ACON	n.d.	0,94	0,15	0,02	0,00	n.d.	3/3	3/3	1/3	0/3	3	97,1	350	7		
Healgen	n.d.	0,93	0,13	0,01	0,00	n.d.	4/4	4/4	1/3	0/4	3-4	96,72	300	6		
möLab	n.d.	0,76	0,12	0,02	0,00	n.d.	2/2	3/3	2/3	0/2	2-3	97,25	300	6		
Teda	n.d.	0,87	0,12	0,00	0,00	n.d.	4/4	4/4	0/3	0/4	3-4	93,87	350	7		
Wondfo	n.d.	0,98	0,11	0,00	0,00	n.d.	2/2	2/3	0/2	0/2	2-3	97,83	400	8		
Abbott	n.d.	1,20	0,09	0,00	0,00	n.d.	4/4	3/4	0/3	0/4	3-4	98,1	300	6		
nal von minden	0,48	0,50	0,09	0,01	0,00	2/2	4/4	4/4	0/3	0/4	2-4	94,1	350	7		
Realy	n.d.	0,89	0,09	0,01	0,00	n.d.	2/2	3/3	0/3	0/2	2-3	92,9	130	2,6		
NanoRepro	0,77	0,56	0,08	0,00	0,00	2/2	3/3	3/3	0/3	0/2	2-4	97,33	500	10		
SD Biosensor	n.d.	1,12	0,07	0,00	0,00	n.d.	4/4	3/4	0/3	0/4	3-4	83,3	300	6		
Deepblue	n.d.	0,67	0,07	0,00	0,00	n.d.	2/2	3/3	0/3	0/2	2-3	96,4	300	6		
OFM	n.d.	0,92	0,07	0,00	0,00	n.d.	3/3	3/3	0/3	0/2	2-3	96,8	400	8		
Hotgen	n.d.	0,68	0,06	0,00	0,00	n.d.	3/3	3/4	0/3	0/3	3-4	95,37	300	6		
fameditec	n.d.	0,51	0,06	0,00	0,00	n.d.	3/3	3/3	0/2	0/2	2-3	96,3	250	5		
Sanicom	1,10	0,63	0,06	0,00	0,00	2/2	3/3	3/3	0/3	0/2	2-4	96,1	1000	20		
RapiGEN	n.d.	0,99	0,05	0,00	0,00	n.d.	3/3	2/3	0/3	0/3	3	96	350	7		
Safecare	0,52	0,43	0,05	0,00	0,00	3/3	3/3	3/3	0/3	0/3	3	97,04	350	7		
Joysbio	0,30	0,31	0,03	0,00	0,00	2/2	3/3	2/3	0/3	0/3	2-3	98,13	350	7		
Ritter	n.d.	0,16	0,02	0,00	0,00	n.d.	2/2	0/3	0/3	0/2	2-3	95,1	500	10		
Joinstar	0,10	0,09	0,02	0,00	0,01	2/2	3/3	1/3	0/3	0/3	2-3	92,2	1000	20		
Hygisun	n.d.	0,36	0,01	0,00	0,00	n.d.	3/3	1/3	0/3	0/3	3	98,94	1000	20		
Lepu Medical	0,07	0,00	0,00	n.d.	0,00	3/7	1/8	0/1	n.d.	0/2	1-8	95,06	150	3		

Figure 1: Quantitative and qualitative evaluation of 32 SARS-CoV-2 AgPOCTs in a rapid sensitivity assessment approach. (A) Investigated AgPOCT are listed with the means of T/C ratios (test band (T) intensity to control (C) band intensity) for each Ct test sample. T/C ratios are color-coded in shades of red (highest values with most intensive red). Blue color highlights zeros indicating the absence of measurable signal at the test band position. Ct16 test sample was only used on AgPOCTs with exceptionally low performance in detection of the Ct21 sample. AgPOCTs are ranked according to their T/C_{Ct25} ratio. (B) Scoring results of visual inspection for all replicates. Full reproducibility of positive scores in all replicates is highlighted in green, positive scores in the majority of replicates in yellow, positive scores in the minority of replicates in orange and no positive scores in any replicate is light red. n.d. = not determined (grey). Double line indicates the limit of reliable detection of SARS-CoV-2 positive samples (reliability defined by reproducibility of positive scores in all or

most replicates of a given Ct test sample). (C) Additional information on investigated AgPOCTs: Sensitivities of AgPOCTs according to the corresponding manufacturer's package insert, volumes of provided lysis buffer and the resulting dilution factor for the Ct test samples ($V = 50 \mu\text{l}$) are given.




Figure 2: Representative images of SARS-CoV-2 AgPOCTs lateral flow test stripes treated with corresponding Ct test samples. Contrast settings were optimized for each AgPOCT example image set in order to ensure best visibility of the test bands. AgPOCT example images are arranged (from left top to right bottom) according to the ranking presented in Figure 1. Red line indicates the limit of reliable detection (see Figure 1A, B).

386 References

- 387 **Bekliz**, M., Adea, K., Essaidi-Laziosi, M., Sacks, J. A., Escadafal, C., Kaiser, L., &
388 Eckerle, I. (2021). Analytical comparison of nine SARS-CoV-2 antigen-detecting
389 rapid diagnostic tests for emerging SARS-CoV-2 variants. *MedRxiv*, 114(June),
390 e00146. Retrieved from <https://doi.org/10.1016/j.sciaf.2019.e00146>
- 391 **Berger**, A., Nsoga, M. T. N., Perez-Rodriguez, F. J., Aad, Y. A., Sattonnet-Roche, P.,
392 Gayet-Ageron, A., ... Eckerle, I. (2021). Diagnostic accuracy of two commercial
393 SARSCoV- 2 antigen-detecting rapid tests at the point of care in community-based
394 testing centers. *PLoS ONE*, 16(3 March 2021), 1–12.
395 <https://doi.org/10.1371/journal.pone.0248921>
- 396 **Brümmer**, L. E., Katzenschlager, S., Gaeddert, M., Erdmann, C., Schmitz, S., Bota,
397 M., ... Denkinger, C. M. (2021). The accuracy of novel antigen rapid diagnostics for
398 SARS-CoV-2: a living systematic review and meta-analysis. *MedRxiv*,
399 2021.02.26.21252546. Retrieved from <https://doi.org/10.1101/2021.02.26.21252546>
- 400 **Corman**, V. M., Haage, V. C., Bleicker, T., Schmidt, M. L., Mühlemann, B.,
401 Zuchowski, M., ... Drosten, C. (2021). Comparison of seven commercial SARS-CoV-
402 2 rapid point-of-care antigen tests: a single-centre laboratory evaluation study. *The*
403 *Lancet Microbe*, 5247(21), 1–9. [https://doi.org/10.1016/S2666-5247\(21\)00056-2](https://doi.org/10.1016/S2666-5247(21)00056-2)
- 404 **Cubas-Atienzar**, A. I., Kontogianni, K., Edwards, T., Buist, K., Thompson, C. R.,
405 Williams, C. T., ... Adams, R. (2021). Limit of detection in different matrices of
406 nineteen commercially available rapid antigen tests for the detection of SARS-CoV-2
407 Liverpool School of Tropical Medicine , Centre for Drugs and Diagnostics , Liverpool ,
408 L3 5QA , UK Liverpool School of Tropical. Retrieved from
409 <https://www.medrxiv.org/content/10.1101/2021.03.19.21253950v1.full.pdf>
- 410 **Dinnes**, J., Deeks, J. J., Adriano, A., Berhane, S., Davenport, C., Dittrich, S., ... Van
411 den Bruel, A. (2020). Rapid, point-of-care antigen and molecular-based tests for
412 diagnosis of SARS-CoV-2 infection. *Cochrane Database of Systematic Reviews*,
413 2020(8). <https://doi.org/10.1002/14651858.CD013705>
- 414 **Federal Institute for Drugs and Medical Devices** (Bundesinstitut für Arzneimittel
415 und Medizinprodukte (BfArM)). Antigen-Tests zum direkten Erregernachweis des
416 Coronavirus.
417 <https://antigentest.bfarm.de/ords/f?p=110:100:16622641307467:::~&tz=2:00>
- 418 **Iglò**, Z., Velzing, J., Van Beek, J., Van de Vijver, D., Aron, G., Ensing, R., ...
419 Molenkamp, R. (2021). Clinical evaluation of roche sd biosensor rapid antigen test for
420 sars-cov-2 in municipal health service testing site, the netherlands. *Emerging*
421 *Infectious Diseases*, 27(5), 1323–1329. <https://doi.org/10.3201/eid2705.204688>
- 422 **Jegerlehner**, S., Suter-riniker, F., Jent, P., Bittel, P., & Nagler, M. (2021). Diagnostic
423 accuracy of a SARS-CoV-2 rapid antigen test in real-life clinical settings. *International*
424 *Journal of Infectious Diseases*, 109, 118–122.
425 <https://doi.org/10.1016/j.ijid.2021.07.010>

- 426 **Kohmer**, N., Toptan, T., Pallas, C., Karaca, O., Pfeiffer, A., Westhaus, S., ...
427 Rabenau, H. F. (2021). The Comparative Clinical Performance of Four SARS-CoV-2
428 Rapid Antigen Tests and Their Correlation to Infectivity In Vitro. *Journal of Clinical*
429 *Medicine*, 10(2), 328. <https://doi.org/10.3390/jcm10020328>
- 430 **Krüger**, L. J., Klein, J. A. F., Tobian, F., Gaeddert, M., Lainati, F., Klemm, S., ...
431 Jones, T. C. (2021). Evaluation of accuracy, exclusivity, limit-of-detection and ease-
432 of-use of LumiraDx™ Antigen-detecting point-of-care device for SARS-CoV-2.
433 *MedRxiv*, 1–37.
- 434 **Merino**, P., Guinea, J., Munoz-Gallego, I., González-Donapetry, P., Galán, J. C.,
435 Antona, N., ... Group, the S. P. T. C.-19 validation. (2021). Multicenter evaluation of
436 the Panbio™ COVID-19 rapid antigen- detection test for the diagnosis of SARS-
437 CoV-2 infection. *Clinical Microbiology and Infection*, 27(January), 758–761.
- 438 **Nordgren**, J., Sharma, S., Olsson, H., Jämtberg, M., Falkeborn, T., Svensson, L., &
439 Hagbom, M. (2021). SARS-CoV-2 rapid antigen test : High sensitivity to detect
440 infectious virus. *Journal of Clinical Virology*, 140(January).
- 441 **Paul Ehrlich Institute** (PEI), Federal Institute for Vaccines and Biomedicines (12
442 July, 2021). Vergleichende Evaluierung der Sensitivität von SARS-CoV-2
443 Antigenschnelltests.
444 [https://www.pei.de/SharedDocs/Downloads/DE/newsroom/dossiers/evaluierung-](https://www.pei.de/SharedDocs/Downloads/DE/newsroom/dossiers/evaluierung-sensitivitaet-sars-cov-2-antigentests-04-12-2020.pdf?__blob=publicationFile&v=48)
445 [sensitivitaet-sars-cov-2-antigentests-04-12-2020.pdf?__blob=publicationFile&v=48](https://www.pei.de/SharedDocs/Downloads/DE/newsroom/dossiers/evaluierung-sensitivitaet-sars-cov-2-antigentests-04-12-2020.pdf?__blob=publicationFile&v=48)
- 446 **Puyskens**, A., Krause, E., Michel, J., Nübling, M., Scheiblaue, H., Bourquain, D., ...
447 Nitsche, A. (2021). Establishment of an evaluation panel for the decentralized
448 technical evaluation of the sensitivity of 31 rapid detection tests for SARS-CoV-2
449 diagnostics. *MedRxiv*.
- 450 **Scheiblaue**, H., Filomena, A., Nitsche, A., Puyskens, A., Corman, V. M., Drosten,
451 C., ... Nübling, C. M. (2021). Comparative sensitivity evaluation for 122 CE-marked
452 SARS-CoV-2 antigen rapid tests. *MedRxiv*, 2021.05.11.21257016. Retrieved from
453 <http://medrxiv.org/content/early/2021/05/12/2021.05.11.21257016.abstract>
- 454 **Schildgen**, V., Demuth, S., Lüsebrink, J., & Schildgen, O. (2021). Limits and
455 opportunities of sars-cov-2 antigen rapid tests: An experienced-based perspective.
456 *Pathogens*, 10(1), 1–7. <https://doi.org/10.3390/pathogens10010038>
- 457 **Seynaeve**, Y., Heylen, J., Fontaine, C., Maclot, F., Meex, C., Diep, A. N., ... Descy,
458 J. (2021). Evaluation of Two Rapid Antigenic Tests for the Detection of SARS-CoV-2
459 in Nasopharyngeal Swabs. *Journal of Clinical Medicine*, (M), 1–9.
- 460 **Stokes**, W., Berenger, B. M., Portnoy, D., Scott, B., Szelewicki, J., Singh, T., ...
461 Tipples, G. (2021). Clinical performance of the Abbott Panbio with nasopharyngeal,
462 throat, and saliva swabs among symptomatic individuals with COVID-19. *European*
463 *Journal of Clinical Microbiology and Infectious Diseases*, 3–8.
464 <https://doi.org/10.1007/s10096-021-04202-9>
- 465 **Strömer**, A., Rose, R., Schäfer, M., Schön, F., Vollersen, A., Lorentz, T., ...
466 Krumbholz, A. (2021). Performance of a point-of-care test for the rapid detection of

- 467 sars-cov-2 antigen. *Microorganisms*, 9(1), 1–11.
468 <https://doi.org/10.3390/microorganisms9010058>
- 469 **Wagenhäuser**, I., Knies, K., Rauschenberger, V., Eisenmann, M., McDonogh, M.,
470 Petri, N., ... Krone, M. (2021). Clinical performance evaluation of SARS-CoV-2 rapid
471 antigen testing in point of care usage in comparison to RT-qPCR. *EBioMedicine*, 69,
472 103455. <https://doi.org/10.1016/j.ebiom.2021.103455>
- 473 **World Health Organization** (WHO; 11 September 2020). Antigen-detection in the
474 diagnosis of SARS-CoV-2 infection using rapid immunoassays: Interim guidance.
475 [WHO/2019-nCoV/Antigen_Detection/2020](https://www.who.int/publications/i/item/WHO/2019-nCoV/Antigen_Detection/2020).

476 **Acknowledgements**

477 We thank Helena Kettern, Vincent T. Jaschinski and Larissa Karl for their flexible
478 help with AgPOCT image acquisition. Furthermore, we thank M. Krogemann for help
479 with AgPOCT result scoring. Additionally, we thank M. Meurer for helpful discussions.